Astria Therapeutics, Inc. financial data

Symbol
ATXS on Nasdaq
Location
22 Boston Wharf Road, 10 Th Floor, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.48K % -39.2%
Debt-to-equity 9.45 % +93.5%
Return On Equity -45 % -46.1%
Return On Assets -41.1 % -40.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57.1M shares +1.15%
Common Stock, Shares, Outstanding 56.4M shares +0%
Entity Public Float 370M USD +32.5%
Common Stock, Value, Issued 57K USD 0%
Weighted Average Number of Shares Outstanding, Basic 58M shares +0.32%
Weighted Average Number of Shares Outstanding, Diluted 58M shares +0.32%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 706K USD
General and Administrative Expense 39.2M USD +21.1%
Operating Income (Loss) -137M USD -17.5%
Nonoperating Income (Expense) 12.5M USD -22.6%
Net Income (Loss) Attributable to Parent -124M USD -24%
Earnings Per Share, Basic -2 USD/shares +0.92%
Earnings Per Share, Diluted -2 USD/shares +0.92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96.3M USD +19%
Cash, Cash Equivalents, and Short-term Investments 228M USD -33.9%
Accounts Receivable, after Allowance for Credit Loss, Current 17.2M USD
Assets, Current 254M USD -27.9%
Operating Lease, Right-of-Use Asset 4.25M USD -21.1%
Other Assets, Noncurrent 14.1M USD +221%
Assets 272M USD -24.8%
Accounts Payable, Current 1.14M USD -11%
Employee-related Liabilities, Current 4.85M USD +34%
Accrued Liabilities, Current 16.5M USD +26.1%
Liabilities, Current 23.5M USD +49.6%
Operating Lease, Liability, Noncurrent 3.06M USD -28.3%
Liabilities 38.6M USD +93.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 56K USD -83.1%
Retained Earnings (Accumulated Deficit) -773M USD -19.1%
Stockholders' Equity Attributable to Parent 233M USD -31.7%
Liabilities and Equity 272M USD -24.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34M USD -78.2%
Net Cash Provided by (Used in) Financing Activities 142M USD +283%
Net Cash Provided by (Used in) Investing Activities 28.6M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 56.4M shares +0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.44M USD -54.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 96.3M USD +19%
Deferred Tax Assets, Valuation Allowance 154M USD +23%
Deferred Tax Assets, Gross 155M USD +24.1%
Operating Lease, Liability 4.46M USD -20.9%
Payments to Acquire Property, Plant, and Equipment 5K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -124M USD -24.7%
Lessee, Operating Lease, Liability, to be Paid 5.05M USD -23.7%
Operating Lease, Liability, Current 1.4M USD +1.96%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.64M USD +1.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.61M USD +2.03%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 586K USD -40.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.53M USD -6.65%
Deferred Tax Assets, Operating Loss Carryforwards 93.7M USD +9.23%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD
Operating Lease, Payments 1.3M USD +30%
Additional Paid in Capital 911M USD +1.78%
Deferred Tax Assets, Net of Valuation Allowance 1.38M USD +1291%
Share-based Payment Arrangement, Expense 15.9M USD +25.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%